reports
QuidelOrtho Corp: 1 director
A director at QuidelOrtho Corp bought 2,150 shares at 46.355USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Quidel and Ortho Announce Expected Closing of Ortho Transaction
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be underta...
Quidel Announces Stockholder Approval of Ortho Acquisition and Busines...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (Nasdaq: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (“Ortho”) by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022. Subject to sanction of a scheme of arrangement to be undertaken by Ortho under Part 26 of the UK Companies Act 2006 (the “Ortho Scheme”) by the High Court of Justice of...
- Jonathan Moreland
WWD WOODWARD INC.
VRAY VIEWRAY INC.
TRNO TERRENO REALTY CORPORATION
TMST TIMKENSTEEL CORP
SXT SENSIENT TECHNOLOGIES CORPORATION
SBUX STARBUCKS CORPORATION
QDEL QUIDEL CORPORATION
PH PARKER-HANNIFIN CORPORATION
OPK OPKO HEALTH INC.
MKL MARKEL CORPORATION
LXP LEXINGTON REALTY TRUST
HRZN HORIZON TECHNOLOGY FINANCE CORP.
HOO HERBALIFE NUTRITION LTD.
DBD DIEBOLD NIXDORF INCORPORATED
COTY COTY INC. CLASS A
COMM COMMSCOPE HOLDING CO. INC.
CNTY CENTURY CASINOS INC.
CMP COMPASS MINERALS INTERNATIONAL INC.
ASPN ASPEN AEROGELS
ANIK ANIKA THERAPEUTICS INC.
DGICA DONEGAL GROUP INC. CL A
UNVR UNIVAR SOLUTIONS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
HEES H&E EQUIPMENT SERVICES INC.
TAIT TAITRON COMPONENTS INC. CL A
RDFN REDFIN CORPORATION
CLF CLIFFS NATURAL RESOURCES INC.
RGCO RGC RESOURCES
OXSQ OXFORD SQUARE CAPITAL
EYEN EYENOVIA INC
USX US XPRESS ENTERPRISES INC
VAPO VAPOTHERM INC
MRBK MERIDIAN
RAPT RAPT THERAPEUTICS
CMTV COMMUNITY BANCORP INC. VT
IHRT IHEARTMEDIA INC. CLASS A
RILY B. RILEY FINANCIAL
EOSE EOS ENERGY ENTERPRISES INC (A)
SKLZ SKILLZ INC (A)
STGW STAGWELL INC
ECVT ECOVYST INC
KLTR KALTURA INC
OPFI OPPFI INC
Quidel Reports First Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Total revenues increased 167% to $1,002.3 million, from $375.3 million in the first quarter of 2021. Total sales of COVID-19 products increased 211% to $836.1 million, from $269.1 million in the first quarter of 2021. Total sales of Influenza products were $89.1 million, as compared to $16.4 million in th...
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference ...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference...
Quidel Announces Preliminary Revenue for First Quarter 2022
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million. COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue® COVID-19 test revenue and approximately $138 ...
Quidel to Present at Raymond James 43rd Annual Institutional Investors...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James & Associates 43rd Annual Institutional Investors Conference to be held at the J.W. Marriott Orlando Grande Lakes hotel in Orlando, Florida on Wednesday, March 9, 2022 at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time). Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on March 9th with a qu...
Quidel Reports Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Highlights Signed definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc ("Ortho"), funded through a combination of cash and newly issued shares in the combined company. Total revenue was $636.9 million, from $809.2 million in the fourth quarter of 2020. Revenue for COVID-19 products w...
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Resu...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2021 financial results after market close on Thursday, February 17, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During th...
Quidel Announces Preliminary Revenue for Fourth Quarter 2021
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million. COVID-19 revenues in the fourth quarter of 2021 are expected to be approximately $510 million. “The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformation...
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022. Douglas Bryant, president and chief executive officer, will present that day at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and fina...
Increased risk weighs on QUIDEL, penalising its rating down to Slight...
The independent financial analyst theScreener just lowered the general evaluation of QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date December 31, 2021, the closing pric...
Quidel’s Antigen Tests Detect the Omicron Variant
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 variants such as Omicron. Mr. Bryant said: “At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception. Recent testing ...
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinica...
SAN DIEGO & RARITAN, N.J.--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho’s closing price on December 22, 2021 and an equity value of approximately $6.0 billion. The transaction is expected to close du...
Quidel Announces Sponsorship and Community Partnership With the Chicag...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has executed a multi-year partnership agreement with the Chicago Blackhawks to sponsor team promotions and community services. In the first year of the partnership agreement, the Blackhawks will work with Quidel to provide QuickVue At-Home OTC COVID-19 Tests free-of-charge to multiple Chicago Blackhawks Foundation community partners to help support local youth and their program staff to continue to learn an...
Quidel Statement on the Omicron Variant
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron. Mr. Bryant said: “At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exce...
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a virtual fireside chat as part of the 33rd Annual Piper Sandler Healthcare Conference. The recording can be accessed by clicking the following link: or via the Investor Relations section of Quidel’s website at . The recording will be available for 90 days. During the fireside chat, Quidel discusses business and financial developments and trends. Quidel’s statements may conta...
Quidel Reports Third Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights Total revenues increased 7% to $509.7 million, from $476.1 million in the third quarter of 2020. Total sales of COVID-19 products increased 7% to $402.6 million, from $375.7 million in the third quarter of 2020. Total sales of Influenza products were $13.8 million, compared to $9.0 million in the thir...
Quidel to Hold Fiscal Third Quarter 2021 Financial Results Conference ...
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal third quarter 2021 financial results after market close on Thursday, November 4, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the confer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.